Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report released on Thursday. They presently have a $35.00 price objective on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 126.98% from the stock’s current price.

The analysts wrote, “. Post 3Q18, we are reiterating our Overweight rating and our 12-month price target of $35. We remain positive on the long-term growth potential of Xtampza, which we expect to be the leading branded extended-release oxycodone over time. We think the company is only in the early stages of building a much-larger portfolio of differentiated opioid and non-opioid pain treatments. Collegium has shown a willingness to work with payers to ensure that the company’s products are available to patients without excessive payer restrictions. Collegium’s lead growth driver is Xtampza, which we continue to believe will replace OxyContin as the largest branded oxycodone ER product.””

A number of other research firms have also issued reports on COLL. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, August 8th. Piper Jaffray Companies set a $34.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, July 11th. Janney Montgomery Scott set a $27.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, August 6th. BidaskClub raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $31.71.

NASDAQ COLL opened at $15.42 on Thursday. The company has a quick ratio of 0.78, a current ratio of 0.82 and a debt-to-equity ratio of 3.94. The company has a market capitalization of $514.27 million, a PE ratio of -6.24 and a beta of 0.24. Collegium Pharmaceutical has a 52-week low of $12.49 and a 52-week high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). The company had revenue of $70.20 million during the quarter, compared to analysts’ expectations of $74.79 million. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. Collegium Pharmaceutical’s revenue for the quarter was up 485.0% compared to the same quarter last year. During the same period last year, the company earned ($0.45) earnings per share. Sell-side analysts predict that Collegium Pharmaceutical will post -1.53 EPS for the current fiscal year.

In related news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $16.53, for a total transaction of $413,250.00. Following the transaction, the director now owns 361,000 shares of the company’s stock, valued at $5,967,330. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 25.76% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of COLL. Royal Bank of Canada raised its position in shares of Collegium Pharmaceutical by 9.4% in the first quarter. Royal Bank of Canada now owns 28,238 shares of the specialty pharmaceutical company’s stock valued at $721,000 after purchasing an additional 2,437 shares during the period. Atria Investments LLC bought a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $201,000. Massachusetts Financial Services Co. MA raised its position in shares of Collegium Pharmaceutical by 1.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 419,656 shares of the specialty pharmaceutical company’s stock valued at $10,009,000 after purchasing an additional 5,818 shares during the period. Commonwealth Equity Services LLC raised its position in shares of Collegium Pharmaceutical by 23.6% in the second quarter. Commonwealth Equity Services LLC now owns 29,539 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 5,640 shares during the period. Finally, Sheaff Brock Investment Advisors LLC raised its position in shares of Collegium Pharmaceutical by 133.8% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 27,000 shares of the specialty pharmaceutical company’s stock valued at $644,000 after purchasing an additional 15,450 shares during the period. 94.41% of the stock is currently owned by hedge funds and other institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Article: Liquidity

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.